Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Erbitux and Avastin Aren’t Cost Effective, NICE Finds

This article was originally published in The Pink Sheet Daily

Executive Summary

Merck KGaA and Roche have 15 days to appeal the ruling regarding metastatic colorectal cancer.

You may also be interested in...

U.K’s NICE To Help Build India’s Health Technology Assessment Board

India is seeking scientific tools like health technology assessments from the United Kingdom’s National Institute for Health Care Excellence as it braces for wider health care coverage and implements a new drug pricing policy.

NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

U.K. Spending Watchdog Rejects Avastin Again For Metastatic Colorectal Cancer

Roche's offer of lump-sum payments to the NHS fails to sway NICE in its second draft evaluation of Avastin for the indication, but because it is not yet a final determination, stakeholders will have an opportunity to weigh in.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts